Beam Therapeutics Secures FDA Pathway for Accelerated Genetic Liver Disease Treatment

Cambridge, Sunday, 11 January 2026.
Beam Therapeutics reached a pivotal FDA agreement allowing biomarker-based accelerated approval for its genetic liver treatment, significantly de-risking its pipeline while extending cash operations into 2029.